CN1816533A - 包含缬沙坦的药物组合物 - Google Patents

包含缬沙坦的药物组合物 Download PDF

Info

Publication number
CN1816533A
CN1816533A CNA2004800186113A CN200480018611A CN1816533A CN 1816533 A CN1816533 A CN 1816533A CN A2004800186113 A CNA2004800186113 A CN A2004800186113A CN 200480018611 A CN200480018611 A CN 200480018611A CN 1816533 A CN1816533 A CN 1816533A
Authority
CN
China
Prior art keywords
visit
patient
trial
patients
valsartan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800186113A
Other languages
English (en)
Chinese (zh)
Inventor
J·N·科恩
R·D·格莱泽
R·拉蒂尼
A·P·马焦尼
G·托尼奥尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1816533A publication Critical patent/CN1816533A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2004800186113A 2003-05-16 2004-05-14 包含缬沙坦的药物组合物 Pending CN1816533A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47113703P 2003-05-16 2003-05-16
US60/471,137 2003-05-16

Publications (1)

Publication Number Publication Date
CN1816533A true CN1816533A (zh) 2006-08-09

Family

ID=33452429

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800186113A Pending CN1816533A (zh) 2003-05-16 2004-05-14 包含缬沙坦的药物组合物

Country Status (10)

Country Link
US (2) US20070054947A1 (enExample)
EP (1) EP1631556A1 (enExample)
JP (1) JP4783733B2 (enExample)
CN (1) CN1816533A (enExample)
AU (2) AU2004238546A1 (enExample)
BR (1) BRPI0410374A (enExample)
CA (1) CA2525665A1 (enExample)
MX (1) MXPA05012299A (enExample)
TW (1) TW200509909A (enExample)
WO (1) WO2004101535A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN115317478A (zh) * 2022-08-26 2022-11-11 宁波大学 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006311723A1 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP2638013A4 (en) 2010-11-12 2014-03-26 Hetero Research Foundation NEW POLYMORPHS OF CALCIUM PIVASTATIN
JPWO2013147137A1 (ja) * 2012-03-30 2015-12-14 味の素株式会社 心不全の治療剤
CA2882771C (en) 2012-08-24 2021-02-23 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
RS59816B1 (sr) * 2013-08-26 2020-02-28 Novartis Ag Nova primena
AU2019285170A1 (en) * 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
JP2021528735A (ja) * 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ アンジオテンシンｉｉ受容体遮断薬医薬組成物による高血圧症の治療方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
SK285863B6 (sk) * 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
JP2002536411A (ja) * 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー Ｘａ因子のラクタム系阻害剤および方法
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
EP1332131A2 (en) * 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002053161A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
US6395782B1 (en) * 2001-03-02 2002-05-28 Wisconsin Alumni Research Foundation Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid
JP2004532250A (ja) * 2001-05-30 2004-10-21 アルテオン インコーポレイテッド 線維性疾患又は他の適応症の治療方法
AU2002363087A1 (en) * 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN106414416A (zh) * 2014-09-09 2017-02-15 上海翰森生物医药科技有限公司 结晶型ARB‑NEPi复合物及其制备方法和应用
CN106414416B (zh) * 2014-09-09 2020-03-27 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN115317478A (zh) * 2022-08-26 2022-11-11 宁波大学 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用
CN115317478B (zh) * 2022-08-26 2023-05-02 宁波大学 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用

Also Published As

Publication number Publication date
AU2004238546A1 (en) 2004-11-25
JP4783733B2 (ja) 2011-09-28
JP2006528949A (ja) 2006-12-28
WO2004101535A1 (en) 2004-11-25
CA2525665A1 (en) 2004-11-25
AU2008246267B2 (en) 2011-02-17
MXPA05012299A (es) 2006-01-30
BRPI0410374A (pt) 2006-06-13
AU2008246267A1 (en) 2008-12-11
TW200509909A (en) 2005-03-16
EP1631556A1 (en) 2006-03-08
US20070054947A1 (en) 2007-03-08
US20090105322A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
CN1089584C (zh) 动脉硬化和黄瘤的治疗
CN1272334C (zh) 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途
CN1250545C (zh) 新的奎宁环衍生物类及含有这类衍生物的药物组合物
US20210340133A1 (en) Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN1478085A (zh) 用于治疗冠状动脉疾病或动脉粥样硬化的abca-1提高化合物
CN1215338A (zh) 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
CN1617729A (zh) 具有胆汁酸输送抑制活性的苯并噻氮䓬类在降低胆固醇血症中的应用
CN1805938A (zh) 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
CN1091006A (zh) 用作降血糖药和治疗早老性痴呆症的化合物
US20140051714A1 (en) Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
CN1575191A (zh) 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病
CN1794994A (zh) 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
CN1338936A (zh) 含有(e)－7－[4－(4－氟苯基)－6－异丙基－2－[甲基(甲基磺酰基)氨基]嘧啶－5基](3r,5s)－3,5－二羟基庚－6－烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物
CN1520314A (zh) 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物
US20140038889A1 (en) Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
CN1816533A (zh) 包含缬沙坦的药物组合物
CN1642904A (zh) 那格列奈的盐
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1777576A (zh) 用于治疗代谢紊乱的化合物
JP7040798B2 (ja) 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
CN1889940A (zh) 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
CN1756740A (zh) 具有2,6－二取代苯乙烯基的含氮杂环衍生物
CN1229141C (zh) 用于治疗心血管病的血管紧张素转化酶抑制剂和环氧－甾族醛固酮拮抗剂的组合物
CN1220490C (zh) 哌嗪环氧乙烷衍生物在制备用于诱导肿瘤细胞死亡的药物中的应用
CN1642557A (zh) 醛固酮受体拮抗剂与烟酸或烟酸衍生物的组合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20060809

C20 Patent right or utility model deemed to be abandoned or is abandoned